A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Patient-Specific iPSC-Derived Cornea Organoids for Investigating Aniridia-Associated Corneal Disorders

137 views

DOI:

10.3791/68556

July 28th, 2026

In This Article

Summary

We describe a protocol for generating cornea organoids from iPSCs derived from aniridia patients, creating a patient-specific model to study corneal disorders. These organoids mimic key structural and functional features, providing a reliable in vitro platform for investigating disease mechanisms, testing potential treatments, and advancing personalized regenerative approaches for anterior eye diseases.

Abstract

Aniridia is a rare congenital eye disorder marked by the partial or complete absence of the iris, and it is often associated with corneal opacification and limbal stem cell deficiency. The underlying genetic mutations, primarily affecting the PAX6 gene, disrupt both the development and function of the cornea. The most common ocular features besides iris defects are nystagmus, foveal hypoplasia, cataract, glaucoma and aniridia-associated keratopathy (AAK). Although in vivo models offer valuable insights into the pathology of aniridia, patient-derived in vitro models are crucial for investigating disease mechanisms and evaluating potential therapies. In this study, we present an in vitro AAK model using patient-derived induced pluripotent stem cells (iPSCs). Our protocol involves the stepwise differentiation of iPSCs into corneal epithelial-like cells within self-assembled three-dimensional organoids, which mimic the native corneal microenvironment. Through the optimization of differentiation culture conditions, we successfully generated corneal organoids that harbor distinct corneal cell populations, recapitulating the key structural and functional attributes of the human cornea.

Introduction

The cornea is an avascular, transparent tissue forming the outermost layer of the eye, consisting mainly of three layers: an epithelial outer layer, a stromal layer containing a collagen-rich extracellular matrix populated by keratocytes, and an endothelial cell layer1. The cornea plays an essential role in vision by protecting internal ocular structures and refracting light.

Aniridia is a rare, congenital panocular disorder primarily caused by heterozygous mutations in the paired box gene 6 (PAX6), a master regulator of ocular development, and is characterized by partial or complete absence of the iris2. In addition to iris hypoplasia or absence, most patients develop progressive corneal abnormalities collectively referred to as aniridia-associated keratopathy (AAK), which includes epithelial defects, limbal stem cell dysfunction, stromal alterations, and progressive corneal opacification, ultimately leading to visual impairment. AAK affects approximately 78%–90% of aniridia patients, with increasing severity over time3. We aimed to establish a detailed and reproducible protocol to generate cornea organoids from aniridia patient-derived induced pluripotent stem cells (iPSCs) to model disease-relevant corneal alterations in vitro. Although animal models and ex vivo studies have provided valuable insights into aniridia pathogenesis, species-specific differences and limited access to patient tissue restrict their translational relevance.

Human iPSC-derived organoids have emerged as powerful in vitro systems for modelling human development and disease4,5. Corneal organoids, in particular, enable the generation of three-dimensional tissue-like structures that more closely resemble native corneal architecture, including stratified epithelial organization, stromal – epithelial interactions, and extracellular matrix deposition, compared to conventional two-dimensional monolayer cultures, which lack spatial organization, physiological cell – cell interactions, and microenvironmental complexity4,5. Several differentiation strategies, including SEAM-based and ocular progenitor-driven approaches, have been reported to generate corneal-like tissues from iPSCs6. These approaches typically involve an initial phase of ocular lineage induction, followed by progressive tissue specification and selection from heterogeneous ocular progenitor populations. Creating cornea organoids provides the opportunity to study different cell types that are present in corneal tissue7,8. Moreover, aniridia patients’ iPSC-derived cornea organoids enable the study of the genetic background of the disease and offer a unique opportunity to study aniridia.

In the present protocol, both wild-type and aniridia-derived iPSC lines are subjected to an identical, multi-stage differentiation strategy involving sequential exposure to differentiation (DM), retinal differentiation (RDM), and corneal differentiation media (CDM) over a prolonged, weeks-long culture period. A critical experimental step is the transition from adherent culture to suspension conditions, during which selected corneal-like regions are maintained to promote epithelial self-organization.

While this approach supports reproducible generation of corneal-like epithelial structures suitable for comparative disease modelling, it does not fully recapitulate complex in vivo features such as neural innervation or complete limbal niche organization, which should be considered when assessing the method’s applicability.

In this context, we describe a standardized protocol for generating cornea organoids from patient-derived iPSCs carrying PAX6 mutations associated with aniridia. Importantly, the differentiation strategy itself is not modified between wild-type and aniridia-derived lines; instead, disease-specific phenotypes emerge from the patient-specific genetic background within an otherwise uniform experimental framework.

Overall, this method provides a robust and reproducible platform for studying corneal development and aniridia-associated disease mechanisms and may serve as a foundation for future mechanistic and translational studies.

Access restricted. Please log in or start a trial to view this content.

Protocol

All procedures were carried out in accordance with the ethics committee's guidelines. The study has been registered in the Human Pluripotent Stem Cell Registry (hPSCreg) database, and the ethical approvals have been documented under the France Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation (MESRI; IE-2018-967)9. The iPSCs are designated with the codes AAKIPSi001-A (AAK1), AAKIPSi002-A (AAK2), AAKIPSi003-A (AAK3), and WT (from health donors). Furthermore, the ethics committee at Hacettepe University has approved the use of this research, as indicated by the reference number 16969557-1213. The human cell lines used in this study required national regulatory authorization at the time of acquisition. The approval was granted under a consortium framework in which one of the authors was involved. While the present manuscript is not directly related to that consortium project, the biological materials utilized were obtained and authorized within that ethical framework. Therefore, the approval from this university was appropriately cited to ensure full regulatory transparency. All details related to the materials, reagents, and equipment used in this protocol are listed in the Table of Materials. All experimental procedures were carried out within a laminar flow cabinet (BSL-2) to maintain a sterile environment. This setup ensures that all materials and equipment used in the study are adequately sterilized, thereby minimizing the risk of contamination and ensuring the integrity of the experimental results.

1. Generation of human induced pluripotent stem cell (hiPSC) derived cornea organoids

  1. Maintenance and initial culture of aniridia-patient-derived human induced pluripotent stem cells (AAK1, AAK2, AAK3)10 under feeder-free conditioned media (Figure 1)
    1. Prepare the following in advance: Coat one well in a 6-well plate with 1 mL of an ice-cold extracellular matrix (ECM) solution at a concentration of 0.1 mg/mL. This coating procedure must be handled on ice, not to solidify the ECM, and must be allowed to incubate at 37 °C for a minimum duration of 30 min, adhering to the manufacturer’s instructions to ensure proper substrate preparation.
    2. Thaw a cryopreserved aliquot of 1 x 106 hiPSC (WT, AAK1, AAK2, AAK3). Do not fully thaw the frozen cells; instead, allow the frozen cell suspension in the cryovial to thaw until approximately half of the volume remains frozen.
    3. Immediately transfer the partially thawed suspension into 1 mL of complete maintenance medium at room temperature (RT) containing 10 µM Rho-associated protein kinase (ROCK) inhibitor, pre-aliquoted in a 15 mL tube. Do not use any pipette during transfer.
    4. Centrifuge at 300 x g for 5 min and discard the supernatant.
    5. Then resuspend the cells in 1 mL of complete maintenance medium containing 10 µM ROCK inhibitor.
    6. Determine the cell density with trypan blue exclusion. Count cells using a hemocytometer after viability staining with trypan blue. Briefly, mix 20 µL of cell suspension 1:1 with 20 µL of 0.4% trypan blue, followed by the addition of 60 µL of PBS, resulting in a final 1:5 dilution of the original cell suspension. From this mixture, load 10 µL into the hemocytometer chamber. Count viable (trypan blue–negative) cells in four large squares. Calculate the average number of cells per square and multiply by 5 (cell suspension dilution factor) and 10,000 to determine the final cell concentration (cells/mL).
      ​Cells/mL = (Average cell count per square) x 5 x 104
    7. Seed the cells onto a pre-coated ECM well in a 6-well plate, ensuring a cell density of 2 x 104 cells/cm2 per well.
    8. Observe the cell morphology and attachment using phase-contrast microscopy at 10x magnification. Then, incubate the 6-well plates at 37 °C with 5% CO₂ to ensure optimal growth conditions.
      NOTE: ROCK inhibitor must only be used overnight while passaging or thawing the cells. During daily medium changes, add the medium gently along the wall of the well. Avoid warming complete maintenance medium in a water bath; instead, equilibrate the medium at room temperature for 15 min before use.
  2. Spontaneous differentiation phase (Day 0 – 2)
    1. Prepare the differentiation media (DM) by mixing the following: 8% KnockOut Serum Replacement (KSR), 1x non-essential amino acids (NEAA), 1x Glutamax, 1x Penicillin-Streptomycin, and Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (DMEM/F-12).
    2. Once hiPSC cultures reach approximately 70%–80% confluence, to induce spontaneous differentiation8, gently aspirate and completely discard the medium, then replace it daily with 1 mL of fresh DM per well until Day 3, when the retinal differentiation phase is initiated according to experimental timeline.
  3. Retinal differentiation phase (Day 3 – 47)
    ​NOTE: Retinal differentiation medium is used for extended periods to allow the formation of heterogeneous ocular progenitor populations.
    1. Prepare the retinal differentiation media (RDM) by mixing the following: 8% KSR, 1x NEAA, 1x Glutamax, 2% B27, 1x Penicillin-Streptomycin, and DMEM/F-12.
    2. After 2 days of spontaneous differentiation, refresh the culture medium daily by carefully aspirating the DM medium and replacing it with 1 mL of fresh RDM medium per well. Continue this for a total of 30 days.
      NOTE: A significant increase in cell density is expected during this 30-day period. It is essential to make microscopic observations of cell density in different areas of each well. To prevent cell lifting, washing must be avoided, and care must be taken during medium changes. Add the media through the wall of the well. Equilibrate the medium at RT for 15 min before use.
    3. By Day 32, cells reach an apparent state of confluence and form multilayered 2.5D aggregates. At this stage, initiate the transition to suspension culture by gently scraping the entire well using a 1000 µL pipette tip. During this process, fragment the cell layer into small clusters.
      ​NOTE: Although all cells are released from the culture surface, multilayered 2.5D aggregates are preferentially collected and transferred to suspension culture (Supplementary Figure 1), as their enrichment promotes faster self-assembly and the formation of larger organoids compared with single cells or monolayer fragments.
    4. Immediately after scraping, collect the resulting cell clusters and transfer them into low-attachment 6-well culture plates containing RDM to establish suspension culture conditions.
    5. Maintain cells in suspension culture for an additional 15 days, with daily medium replacement using 2 mL of fresh RDM per well. During the first 2 days of suspension culture, avoid medium change to prevent loss of small cell clusters. During suspension culture, cells gradually self-organize and give rise to 3D, transparent, corneal-like structures, monitor regularly by phase-contrast microscopy at 4x and 10x magnification.
  4. Corneal differentiation phase (Day 48 – 90)
    1. Prepare the corneal differentiation media (CDM) by mixing the following: 8% KOSR, 1x NEAA, 1x Glutamax, 1x N2-MAX, 1x Insulin-Transferrin-Selenium, 5 ng/mL FGF2, 10 ng/mL EGF, and DMEM/F-12.
    2. After the initial 15-days (from Day 32 – Day 47) of suspension culture in low-attachment plates (37 °C, 5% CO₂), replace RDM with CDM while maintaining the aggregates under suspension conditions at Day 47. Refresh CDM every other day with 2 mL per well, ensuring organoids are always fully submerged in the culture medium. During this period, transparent, bubble-like corneal primordial (CP) structures progressively emerge.
    3. Continue suspension culture in CDM until Day 90, allowing further maturation and spatial segregation of transparent CP regions from more opaque tissue compartments.
    4. At Day 90, mechanically separate transparent CP regions from more opaque tissue compartments using sterilized forceps and tweezers when CP-specific downstream analyses are intended.
      ​NOTE: Mechanical isolation of CP regions is performed when analyses specifically require CP-enriched structures. If other tissue compartments or overall organoid architecture are of interest, organoids may be maintained intact to preserve structural heterogeneity.
    5. Continue the suspension culture in CDM for either isolated CP structures or intact organoids, depending on the experimental objective.

2. Characterization of corneal organoids

  1. Morphological and structural evaluation of organoids
    1. Monitor cornea organoids regularly using brightfield microscopy at 4x and 10x magnification. Evaluate size, transparency, and overall morphology at defined time points and document structural changes by image acquisition.
  2. Immunofluorescence-based characterization
    1. Cornea organoid fixation
      1. Prepare 4% PFA and 30% sucrose solutions before fixation. Take the cornea organoid from culture with an autoclaved scooper. Transfer the organoid into the 4% PFA in a 1.5 mL tube and incubate for 20 min at room temperature.
      2. After incubation, discard the PFA from the tube carefully without damaging the cornea organoid. Add 1 mL of 30% sucrose solution to the tube and place it at 4 °C. After 24 h, prepare and label 5 mL tubes and liquid nitrogen for OCT fixation.
      3. Discard the sucrose solution from the tube carefully. Transfer the organoid into the sterile scooper. With a 20 µL pipette, remove the excess sucrose solution from the organoid carefully.
      4. Pour OCT into the 5 mL tube cap, and place the organoid into the OCT. Use another sterile scooper to transfer the organoid into the OCT-containing cap.
      5. Add OCT to cover the surface of the cornea organoid. Pop the balloons in the OCT with a needle to obtain clear sections of the organoid.
      6. Close the cap of the 5 mL tubes and use tweezers to dip into the liquid nitrogen. Store the samples in -20 °C until sectioning.
      7. Section them at 5 µm thickness using a cryostat and also store them at -20 °C till staining. Maintain consistent section thickness and tissue orientation to ensure reproducible staining.
    2. IF staining
      1. To prepare cornea organoid sections for IF staining, wash the slides 3x with PBS-T (0.3% Triton X-100) at RT for 10 min.
      2. Clean the slide with tissue paper and make a border with PAP pen. Add an appropriate amount of blocking solution to completely cover the tissue section (typically 100 – 200 µL per slide, depending on the PAP pen boundary) and incubate it at RT for 1 h.
      3. Aspirate the blocking solution and make a border with the PAP pen. Add the 150 μl of primary Ab (PAX6, p63, OCT3/4, NANOG, Na+/K+-ATPase, AQP1, CK3, CK5, CK14, CK19, N-cad, KERA, COLIV, the dilution rates are listed in the Table of Materials) solutions onto the slide and incubate it at RT for 1 h.
      4. Wash 2x with PBS-T (0.3% Triton X-100) at RT for 10 min. Make the border again with a PAP pen.
      5. Add the 150 μl of secondary Ab solution (Anti Rabbit-488, Anti Mouse-594, the dilution rates are listed in the Table of Materials) onto the slide and incubate it at RT under dark conditions for 2 h. Wash 2x with PBS-T (0.3% Triton-X) at RT for 10 min. Clean the slides and mount with DAPI solution.
      6. For undifferentiated iPSCs, perform blocking and permeabilization after fixation and proceed with staining using the same protocol. Visualize stained samples using fluorescence or confocal microscopy at 4x and 10x magnification.

Access restricted. Please log in or start a trial to view this content.

Results

Stemness of human induced pluripotent stem cells (hiPSCs)

To assess the stemness of human iPSCs used in the experiments, we performed brightfield imaging, immunostaining, and qRT-PCR analysis. We evaluated the expression of key pluripotency markers, including OCT3/4, SOX2, and NANOG, which are core transcription factors required for the maintenance of pluripotency and self-renewal in human pluripotent stem cells11.

B...

Access restricted. Please log in or start a trial to view this content.

Discussion

Comparative analysis between control organoids and those derived from aniridia patients reveals defects in epithelial stratification, abnormal extracellular matrix deposition, and dysregulated expression of the PAX6 gene9.

The growth rate of iPSCs derived from different aniridia patient samples, specifically AAK1, AAK2, and AAK3 lines, exhibits variability, potentially reflecting the underlying genetic diversity, caused primarily by mutations in the PAX6

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have not disclosed.

Acknowledgements

This study is funded by TÜBİTAK 121N276 and the European Joint Programme on Rare Diseases and partially supported by European Union (Horizon 2020 ERA Chair Program, RareBoost Project Grant no: 952346). A.C.K. is supported by YÖK 100/2000 PhD scholarship and TÜBİTAK-BİDEB 2211A fellowships.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
10 mL serological pipettesZA BioteknoLabselect SP-003-10
15 mL Conical Tubes Labselect CT-002-15A
2 mL serological pipettesLabselect Labselect SP-003-2
5 mL serological pipettesCleanteksBiofil GSP010005
50 mL Conical TubesGolden Gate CT-002-50
50 mL serological pipettesBIOFILLGSP020050
Anti Mouse 594Jackson Immuno715-585-150Dilution Range: 1:100 - 1:800
Anti Rabbit 488 Jackson Immuno711-545-152Dilution Range: 1:100 - 1:800
Autoclave VAPOUR-Line liteVWR chemicalsVAPOUR-Lineeco 25
B27 SupplementGIBCO12587010with vitamin A
Benchtop CentrifugeEppendorf5702
Benchtop microscope DMI1OlympusCKX41
Biological Safety Cabinets Class IIThermoSafe 2020
Bovine Serum Albumin (BSA)Sigma-AldrichA8806
CellBanker 1Worthington IndustriesLABS-20K
Coverslips 24 mm x 50 mmISOLAB280
Cryomatrix, OCTFisher Healthcare30226281
CryovialBioSigmaN403522
DAPINEOFROXX 1322
DAPINEOFROXX 15390.5 ug/mL
DMEM/F12 MediaGIBCO 31330-038
Dulbecco's Phosphate-bufferd Saline (DPBS)Gibco141901441X
EGFGIBCOPHG0311
Ethanol 100%Sigma64-17-5
Ethanol 70%Sigma64-17-5Ethanol dilutions
Extracellular Matrix (ECM)Corning354277LDEV-free
FGF2GIBCOPHG0024
GlutaMaxGIBCO35050061
GoTaq Master MixPromegaM7123
IncubatorMemmert INCO 153 med44043
Insulin-Selenium-TransferrinGIBCO41400045
KnockOut Serum (KOSR)GIBCO10828028
Microtome RM2235LeicaRM2235
Mounting mediumabcamab104135
mTSER MediaSTEMCELL85850
Mutiwell Culture Plates (6-well)CORNING   3516
N2 SupplementR&DAR003
Non-essential amino acids (NEAA)LONZABE13-114E
P20, P200 and P1000 pipettesGilsonF167350
ParaffinVWR chemicals10048502
Paraformaldehyde Sigma-AldrichF8775
Primer Antibody Aquaporin mAbabcamab9566Dilution Range: 1:50-1:200
Primer Antibody CK14Santa Cruz Biotechnology sc-53253Dilution Range: 1:50-1:500
Primer Antibody CK19ProteinTech14965-1-APDilution Range: 1:150-1:600
Primer Antibody CK3NOVUSNBP2-91997 0.1 MLDilution Range: 1:50-1:200
Primer Antibody CK5Thermo MA517057Dilution Range: 1:200-1:1000
Primer Antibody Collagen Type IVabcamab6586Dilution Range: 1:100-1:500
Primer Antibody KeratocanBiossbs-11054RDilution Range: 1:50-1:200
Primer Antibody Na/K - ATPaseSanta Cruz Biotechnologysc-21712Dilution Range: 1:50-1:500
Primer Antibody N-Cadherinabcamab76011Dilution Range: 1:50-1:500
Primer Antibody p63SANTACRUZ   sc-25268Dilution Range: 1:50-1:500
Primer Antibody Pax6NovusNBP2-44576Dilution Range: 1:50-1:200
RNA isolation kitMacherey–Nagel 740984.50
Rock Inihibitor (Y-27632)TOCRIS1254
SlidesStarFrostMBB-0302-55AAdhesive, ground
Stainless steel forceps no:5Sigma F6521-1EA
Stainless Stell Scalpel Sterile N 21Swann-Morton1033060
The OneScript Plus cDNA Synthesis Kit Applied Biological MaterialsG236
Triton-X100NEOFROXX 8500
TRIzol reagentThermo15596026
Trypan blueGIBCO15250061
Ultra low attachment (ULA) 6-well  plate Corning3471
Water bathNüveNb9

References

  1. Hassell, J. R., Birk, D. E. The molecular basis of corneal transparency. Exp Eye Res. 91 (3), 326-335 (2010).
  2. Daruich, A., et al. Congenital aniridia beyond black eyes: From phenotype and novel genetic mechanisms to innovative therapeutic approaches. Prog Retin Eye Res. 95, 101133(2023).
  3. Eden, U., Riise, R., Tornqvist, K. Corneal involvement in congenital aniridia. Cornea. 29 (10), 1096-1102 (2010).
  4. Huch, M., Koo, B. K. Modeling mouse and human development using organoid cultures. Development. 142 (18), 3113-3125 (2015).
  5. Hofer, M., Lutolf, M. P. Engineering organoids. Nat Rev Mater. 6 (5), 402-420 (2021).
  6. Yin, X., et al. Engineering Stem Cell Organoids. Cell Stem Cell. 18 (1), 25-38 (2016).
  7. Foster, J. W., et al. Cornea organoids from human induced pluripotent stem cells. Sci Rep. 7, 41286(2017).
  8. Susaimanickam, P. J., et al. Generating minicorneal organoids from human induced pluripotent stem cells. Development. 144 (13), 2338-2351 (2017).
  9. Koc, A. C., et al. Patient-derived cornea organoid model to study metabolomic characterization of rare disease: aniridia-associated keratopathy. BMC Ophthalmol. 25 (1), 14(2025).
  10. Ilmarinen, T., et al. Production and Limbal Lineage Commitment of Aniridia Patient-Derived Induced Pluripotent Stem Cells. Stem Cells. 41 (12), 1133-1141 (2023).
  11. Chambers, I., et al. Nanog safeguards pluripotency and mediates germline development. Nature. 450 (7173), 1230-1234 (2007).
  12. Okur, F. V., Cevher, I., Ozdemir, C., Kocaefe, C., Cetinkaya, D. U. Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods. Stem Cell Res Ther. 10 (1), 211(2019).
  13. Nakano, T., et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell. 10 (6), 771-785 (2012).
  14. Lima Cunha, D., Arno, G., Corton, M., Moosajee, M. The Spectrum of PAX6 Mutations and Genotype-Phenotype Correlations in the Eye. Genes (Basel). 10 (12), 1050(2019).
  15. Hayashi, R., et al. Co-ordinated ocular development from human iPS cells and recovery of corneal function. Nature. 531 (7594), 376-380 (2016).
  16. Gonzalez, G., Sasamoto, Y., Ksander, B. R., Frank, M. H., Frank, N. Y. Limbal stem cells: identity, developmental origin, and therapeutic potential. Wiley Interdiscip Rev Dev Biol. 7 (2), (2018).
  17. Ji, H. P., et al. MicroRNA-28 potentially regulates the photoreceptor lineage commitment of Muller glia-derived progenitors. Sci Rep. 7 (1), 11374(2017).
  18. Hatou, S., et al. Role of insulin in regulation of Na+-/K+-dependent ATPase activity and pump function in corneal endothelial cells. Invest Ophthalmol Vis Sci. 51 (8), 3935-3942 (2010).
  19. Higa, K., et al. Aquaporin 1-positive stromal niche-like cells directly interact with N-cadherin-positive clusters in the basal limbal epithelium. Stem Cell Res. 10 (2), 147-155 (2013).
  20. Chen, Q., et al. Stromal fibroblasts derived from mammary gland of bovine with mastitis display inflammation-specific changes. Sci Rep. 6, 27462(2016).
  21. Soiberman, U., Foster, J. W., Jun, A. S., Chakravarti, S. Pathophysiology of Keratoconus: What Do We Know Today. Open Ophthalmol J. 11, 252-261 (2017).
  22. Lima Cunha, D., et al. Restoration of functional PAX6 in aniridia patient iPSC-derived ocular tissue models using repurposed nonsense suppression drugs. Mol Ther Nucleic Acids. 33, 240-253 (2023).
  23. Harding, P., et al. Variant-specific disruption to notch signalling in PAX6 microphthalmia and aniridia patient-derived hiPSC optic cup-like organoids. Biochim Biophys Acta Mol Basis Dis. 1871 (6), 167869(2025).
  24. Cunha, D. L., Smits, J., Zhou, H. Q., Moosajee, M. Transcriptomic analysis of aniridia iPSC-derived limbal epithelial stem cells reveals early changes linked to the limbal niche. Invest Ophthalmol Vis Sci. 64 (8), 2821(2023).
  25. Harding, P., et al. Generation of human iPSC line (UCLi013-A) from a patient with microphthalmia and aniridia, carrying a heterozygous missense mutation c.372C>A p.(Asn124Lys) in. Stem Cell Res. 51, (2021).
  26. Theerakittayakorn, K., et al. Differentiation Induction of Human Stem Cells for Corneal Epithelial Regeneration. Int J Mol Sci. 21 (21), (2020).
  27. Bar-Nur, O., et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Methods. 11 (11), 1170-1176 (2014).
  28. Maiti, G., et al. Single cell RNA-seq of human cornea organoids identifies cell fates of a developing immature cornea. PNAS Nexus. 1 (5), pgac246(2022).
  29. Dorot, O., et al. The antipsychotropic drug Duloxetine rescues PAX6 haploinsufficiency of mutant limbal stem cells through inhibition of the MEK/ERK signaling pathway. Ocul Surf. 23, 140-142 (2022).
  30. van Velthoven, A. J. H., et al. Future directions in managing aniridia-associated keratopathy. Surv Ophthalmol. 68 (5), 940-956 (2023).
  31. Kocak, G., et al. Generation of Anterior Segment of the Eye Cells from hiPSCs in Microfluidic Platforms. Adv Biol (Weinh). 8 (5), e2400018(2024).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Medicineorganoiddisease model
Video Coming Soon